ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 53 filers reported holding ALIGOS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $180,463 | -27.6% | 241,503 | -5.9% | 0.00% | – |
| Q2 2023 | $249,150 | +42.6% | 256,592 | +28.4% | 0.00% | – |
| Q1 2023 | $174,675 | +91834.2% | 199,858 | 0.0% | 0.00% | – |
| Q4 2022 | $190 | -99.9% | 199,858 | +5.0% | 0.00% | – |
| Q3 2022 | $209,000 | -9.1% | 190,418 | 0.0% | 0.00% | – |
| Q2 2022 | $230,000 | -69.8% | 190,418 | -46.3% | 0.00% | – |
| Q1 2022 | $762,000 | -81.6% | 354,787 | +1.5% | 0.00% | – |
| Q4 2021 | $4,149,000 | -14.7% | 349,576 | +11.5% | 0.00% | -100.0% |
| Q3 2021 | $4,864,000 | -6.6% | 313,655 | +22.8% | 0.00% | 0.0% |
| Q2 2021 | $5,205,000 | +28.1% | 255,348 | +42.9% | 0.00% | 0.0% |
| Q1 2021 | $4,064,000 | -17.7% | 178,752 | +0.0% | 0.00% | 0.0% |
| Q4 2020 | $4,940,000 | – | 178,694 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $2,028,013 | 4.23% |
| TANG CAPITAL MANAGEMENT LLC | 3,424,800 | $2,993,275 | 0.45% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $649,570 | 0.27% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $552,269 | 0.23% |
| Vivo Capital, LLC | 3,547,030 | $3,100,104 | 0.22% |
| Newtyn Management, LLC | 1,021,461 | $892,757 | 0.18% |
| Logos Global Management LP | 1,000,000 | $874,000 | 0.12% |
| EcoR1 Capital, LLC | 3,948,360 | $3,450,867 | 0.11% |
| HHLR ADVISORS, LTD. | 2,309,764 | $2,018,734 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,814,774 | 0.01% |